BioWorld International articles from January 2006

BioWorld International archives from January 2006

UK ending 2005 with bang: AstraZeneca buying KuDOS.
January 4, 2006... LONDON -- KuDOS Ltd. was acquired by AstraZeneca plc for 121.5 million [pounds sterling] (US$210 million) in cash, rounding off the most successful month in the history of the UK biotech industry, with five deals totaling more than $1.3 billion...

Tibotec submits NDA: new protease inhibitor for HIV.
January 4, 2006... Tibotec Pharmaceuticals Inc. submitted a new drug application for TMC1 14, its protease inhibitor for HIV, based on 24-week findings from two Phase IIb studies, thereby moving another compound officially nearer to the competitive space--though...

Genetic study offers up clues for sepsis survival.
January 4, 2006... LONDON -- Whether someone survives the multiple organ failure that can follow severe infection--a condition known as sepsis--might depend on whether they have a certain variant of DNA within their mitochondria. New research showed that...

Santhera spins out Graffinity through management buyout.(Santhera Pharmaceuticals AG )
January 4, 2006... Santhera Pharmaceuticals AG divested its drug discovery unit via a management buyout in order to focus on its clinical and preclinical development pipeline. The move revives the Graffinity name--it was one of the participants, along with...

BioProgress plc, of Cambridgeshire, UK, acquired France-based Dexo SA in a cash and shares deal worth 12.5 million [euro] (US$15 million).(Other News To Note)(Brief Article)
January 4, 2006... BioProgress plc, of Cambridgeshire, UK, acquired France-based Dexo SA in a cash and shares deal worth 12.5 million [euro] (US$15 million). At the same time, BioProgress said it is moving its headquarters from March to Cambridge. The acquisition...

Galapagos NV.(Other News To Note)
January 4, 2006... Galapagos NV, of Mechelen, Belgium, and Prolysis Ltd., of Oxford, UK, extended a research collaboration started last year, in which BioFocus, the service division of Galapagos, is working with Prolysis to identify dual enzyme inhibitors aimed...

Medivir AB, of Huddinge, Sweden, said under its hepatitis C virus research collaboration with Tibotec Pharmaceuticals Ltd., of Cork, Ireland, the companies recently have designated a candidate drug.(Other News To Note)
January 4, 2006... Medivir AB, of Huddinge, Sweden, said under its hepatitis C virus research collaboration with Tibotec Pharmaceuticals Ltd., of Cork, Ireland, the companies recently have designated a candidate drug. The aim of the collaboration is to identify...

Regenera Ltd.(acquires Advanced Ocular Systems Inc.)(Brief Article)
January 4, 2006... Regenera Ltd., of Perth, Australia, said its shareholders approved the company's merger with Marblehead, Mass.-based Advanced Ocular Systems Inc. in a deal valued at $31 million. Regenera agreed to issue a maximum of 100.8 million shares to AOS...

Vita Genomics, of Taipei, Taiwan, and Affymetrix Inc., of Santa Clara, Calif., said that Affymetrix granted Vita and its fully owned subsidiary.(Other News To Note)
January 4, 2006... Vita Genomics, of Taipei, Taiwan, and Affymetrix Inc., of Santa Clara, Calif., said that Affymetrix granted Vita and its fully owned subsidiary, Shanghai GeneCore Biotechnologies, nonexclusive access to Affymetrix microarray technology to...